Clinicopathological Features and Long-Term Prognostic Role of Human Epidermal Growth Factor Receptor-2 Low Expression in Chinese Patients with Early Breast Cancer:A Single-Institution Study  

作　　者：KONG Zi Qing LIU Li Qun HUANG De Qin WANG Yu Tong LI Jing Jie ZHANG Zheng WANG Xi Xi LIU Chuan Ling ZHANG Ya Di SHAO Jia Kang ZHU Yi Min CHEN Yi Meng LIU Mei ZHAO Wei Hong 

机构地区：[1]Medical School of Chinese PLA,Beijing 100853,China [2]Department of Medical Oncology,the First Medical Center,General Hospital of the Chinese People’s Liberation Army,Beijing 100853,China [3]Nankai University School of Medicine,Tianjin 300071,China [4]Department of Medical Oncology,the Fifth Medical Center,General Hospital of the Chinese People’s Liberation Army,Beijing 100039,China [5]Department of Medical Oncology,Xi'an Jiaotong University,Xi’an 710061,Shaanxi,China [6]Department of Pathology,the Sixth Medical Center,General Hospital of the Chinese People’s Liberation Army,Beijing 100037,China

出　　处：《Biomedical and Environmental Sciences》2024年第5期457-470,共14页生物医学与环境科学（英文版）

基　　金：supported by grants from the Health Care Special Project,Grant/Award Number:17BJZ40。

摘　　要：Objective This study aimed to comprehensively analyze and compare the clinicopathological features and prognosis of Chinese patients with human epidermal growth factor receptor 2(HER2)-low early breast cancer(BC)and HER2-IHC0 BC.Methods Patients diagnosed with HER2-negative BC(N=999)at our institution between January2011 and December 2015 formed our study population.Clinicopathological characteristics,association between estrogen receptor(ER)expression and HER2-low,and evolution of HER2 immunohistochemical(IHC)score were assessed.Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes(5-year follow-up)between the HER2-IHC0 and HER2-low groups.Results HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor(PgR)positivity than HER2-IHC0 BC group(P<0.001).The rate of HER2-low status increased with increasing ER expression levels(Mantel-Haenszelχ^(2)test,P<0.001,Pearson’s R=0.159,P<0.001).Survival analysis revealed a significantly longer overall survival(OS)in HER2-low BC group than in HER2-IHC0 group(P=0.007)in the whole cohort and the hormone receptor(HR)-negative group.There were no significant differences between the two groups in terms of disease-free survival(DFS).The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.Conclusion HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.

关 键 词：HER2 HER2-low Breast cancer Estrogen receptor Trastuzumab deruxtecan 

分 类 号：R737.9[医药卫生—肿瘤]